This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?
by Zacks Equity Research
Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Maxar (MAXR) This Earnings Season?
by Zacks Equity Research
Lower revenues in the Space Infrastructure segment are likely to get reflected on Maxar's (MAXR) first-quarter 2020 results.
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)
by Zacks Equity Research
Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for April 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Fate Therapeutics (FATE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FATE) Outperforming Other Medical Stocks This Year?
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?
by Zacks Equity Research
Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Fate Therapeutics Surges on Immunotherapy Deal With J&J
by Zacks Equity Research
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 5.13% and 52.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
Fate (FATE) Announces Encouraging Data on Immunotherapies
by Zacks Equity Research
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.
Company News for Dec 10, 2019
by Zacks Equity Research
Companies in the news are: ARQL, THOR, CGC, FATE
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.26% and 26.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?